Komori
Disclosure4586Medrx Co.,Ltd.Pharmaceuticals

Notice of Approval for the Change in Market Segment to the Tokyo Stock Exchange's Standard Market

Following approval by the Tokyo Stock Exchange, our shares will change market segments from the Tokyo Stock Exchange Growth Market to the Tokyo Stock Exchange Standard Market effective 7 October 2026.

Worth reading
53Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Decision and Details

Tokyo Stock Exchange, Inc. (TSE)

Change in Market Segment to the Tokyo Stock Exchange Standard Market

Decision30 September 2026
Implementation7 October 2026 (scheduled market segment change date)
Going forwardEffective 7 October 2026, our shares will change market segments from the Tokyo Stock Exchange Growth Market to the Tokyo Stock Exchange Standard Market.
Reason

No specific reason for the change in market segment is stated. The company says that, even after moving to the Standard Market, it will maintain its management philosophy, pursue research and development and commercialization, and aim for sustained growth and increased corporate value.

Decision and Details
ItemDetails
Matter CoveredChange in Market Segment to the Tokyo Stock Exchange Standard Market
Decision-Making BodyTokyo Stock Exchange, Inc. (TSE)
Decision Date30 September 2026
Implementation Date7 October 2026 (scheduled market segment change date)
ReasonNo specific reason for the change in market segment is stated. The company says that, even after moving to the Standard Market, it will maintain its management philosophy, pursue research and development and commercialization, and aim for sustained growth and increased corporate value.
Future plansEffective 7 October 2026, our shares will change market segments from the Tokyo Stock Exchange Growth Market to the Tokyo Stock Exchange Standard Market.
Items this document does not state (6)
Period CoveredAmountQuantity / scaleImpact on Business PerformanceGoverning RuleRelated previous disclosures

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

No specific reason for the change in market segment is stated. The company says that, even after moving to the Standard Market, it will maintain its management philosophy, continue research and development and commercialization, and aim for sustained growth and increased corporate value.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Approval for the Change in Market Segment to the Tokyo Stock Exchange's Standard Market | Medrx Co.,Ltd. (4586) timely disclosure | Komori